<div id="readability-page-1"><p>JonesTrading analyst Boris Peaker reiterated a Buy rating on Prime Medicine, Inc. today and set a price target of $5.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Peaker is a 5-star analyst with an average return of <span>19.6%</span> and a 45.36% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Relay Therapeutics, Nuvation Bio, and OnKure Therapeutics.</p> <p>In addition to JonesTrading, Prime Medicine, Inc. also received a Buy from Chardan Capital’s Geulah Livshits in a report issued today. However, on the same day, H.C. Wainwright reiterated a Hold rating on Prime Medicine, Inc. (NASDAQ: PRME).</p></div>

PRME

<p>JonesTrading analyst Boris Peaker has reaffirmed a Buy rating on Prime Medicine, Inc. (PRME) with a price target of $5.00. Peaker, a 5-star analyst, has an average return of 19.6% and a 45.36% success rate. Additionally, Chardan Capital's Geulah Livshits also issued a Buy rating for the company today, while H.C. Wainwright maintained a Hold rating on PRME.</p>

Tip Ranks

Prime Medicine

SPDR S&P Biotech

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Health Care Select Sector SPDR

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

VG Health

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

iShares US Pharma

Relay Therapeutics

Nuvation Bio

OnKure Therapeutics

NUVATION BIO INC C/WTS 10/02/2026 (TO PUR COM)

JonesTrading Reaffirms Their Buy Rating on Prime Medicine, Inc. (PRME)